Introduction
============

Liver X receptor (LXR) α and β are transcription factors belonging to the nuclear receptor (NR) superfamily.^[@bib1]^ They bind to DNA as heterodimers with retinoid X receptor (RXR) (for a review on RXR^[@bib2]^). Most NRs, including LXRs, are activated by small lipophilic ligands. For LXR, these are cholesterol derivatives termed oxysterols (for review on oxysterols^[@bib3]^). Since their initial discovery in 1995, LXRs have emerged as powerful metabolic regulators in different tissues and cell types. For example, LXRs have been shown to regulate cholesterol, bile acid, triglyceride and glucose homeostasis as well as inflammation and intestinal lipid absorption. In addition, murine studies have demonstrated positive effects of LXR agonists on insulin resistance and atherosclerosis. LXRs have therefore been proposed as attractive pharmacological targets in humans. A caveat in this respect is the complex and sometimes opposing effects of LXR activation in different tissues and species *in vitro* and *in vivo*. Although recent reviews have made attempts to integrate and discuss the different physiological processes regulated by LXRs, their focus has primarily been on non-adipose tissues.^[@bib4],\ [@bib5],\ [@bib6]^ In this review, we specifically address the role of LXR in adipocytes and adipose tissue, and, where available, compare the data obtained in rodent and human experimental systems. The sometimes-conflicting results obtained by different research groups complicate the interpretation of what LXR does, not only at the cellular but also at the whole-body level.

LXR genes and expression in adipose tissue
==========================================

LXRα and LXRβ are coded by the *NR1H3* and *NR1H2* genes, respectively. At the amino acid level, the two isoforms share about 78% identity in the DNA- and ligand-binding domains.^[@bib7]^ In humans, several single nucleotide polymorphisms (SNPs) have been reported in both genes (further discussed below).^[@bib8],\ [@bib9],\ [@bib10]^

Both LXRα and β are expressed in mature murine and human adipocytes. Although expression of LXRα is upregulated during fat cell differentiation, LXRβ is not regulated by adipogenesis.^[@bib11],\ [@bib12],\ [@bib13]^ Three different splice variants of LXRα^[@bib1],\ [@bib2],\ [@bib3]^ have been reported, where the most abundant and active form is the LXRα1 variant, which is present in all tissues expressing LXRα.^[@bib14]^ LXRα2 is predominantly expressed in human testis and cancer cell lines, and lacks the first 45 amino acids present in LXRα1. LXRα3 is generated through an alternative recognition of a 3′-splice site in exon 6 and lacks 50 amino acids within the ligand-binding domain. Expression of LXRα3 has been reported in human lung, thyroid gland, spleen and cancer cell lines. The levels of different LXRα isoforms in adipose tissue have not yet been reported in the literature.

Regulation of LXR activity in adipocytes
========================================

Upon activation, LXRs bind to DNA at specific sites termed LXR response elements (LXREs) (for review see Viennois *et al.*^[@bib4]^, Baranowski *et al.*^[@bib6]^). As for other NRs, the activity and DNA binding of LXR is regulated by a complex interaction between ligands, co-factors and post-translational modifications.

Ligands and agonists
--------------------

Adipocytes harbor large amounts of nonesterified cholesterol---a potential source of natural ligands for LXR.^[@bib15]^ It has therefore been postulated that LXR in adipocytes may be constitutively active. In addition, multiple *in vivo* and *in vitro* studies in adipose cells have demonstrated that endogenously expressed LXRs can be further activated by treatments with oxysterols and synthetic LXR agonists. For instance, oxysterol 22(R)-hydroxycholesterol has been shown to induce LXR-responsive genes in differentiated murine 3T3-L1 adipocytes.^[@bib11],\ [@bib12]^ Two synthetic non-steroidal LXR agonists, T091317^(ref.\ [@bib16])^ and GW3965,^[@bib17]^ have been widely used both *in vitro* and *in vivo*. The latter two compounds display similar potencies in activating LXR in adipocytes.^[@bib18]^ However, T091317 is not LXR selective as it can also act as an agonist for the farnesoid X receptor and pregnane X receptor.^[@bib19],\ [@bib20]^ As farnesoid X receptor is expressed in 3T3-L1 and murine primary adipocytes,^[@bib21]^ this could influence the results obtained using T091317 in these cells. In contrast, human adipocytes do not express either farnesoid X receptor or pregnane X receptor (Laurencikiene, unpublished observations). Effects of other synthetic LXR activity-modulating compounds^[@bib22]^ have not been investigated in fat cells.

The stereoisomeric form of the ligand is obviously important as 22(S)-hydroxycholesterol has been shown to act as an LXR antagonist in 3T3-L1 adipocytes,^[@bib11]^ confirming that LXR possesses some basal activity in fat cells. In hepatocytes, polyunsaturated fatty acids can also act as antagonists in the induction of the LXR-response gene sterol regulatory element-binding protein-1 (*SREBP-1*) (for review see Madsen *et al.*^[@bib23]^). However, only indirect evidence suggests that a similar interaction might take place in adipocytes.^[@bib24]^

Co-factors
----------

Apart from ligands, transcriptional co-regulators provide the context and pathway specificity for LXR signaling. Several co-factors have been shown to form part of the LXR transcriptional complex ([Figure 1](#fig1){ref-type="fig"}). In the ligand-free, repressed, state LXRs associate with NR co-repressor (NCoR) and associate somewhat weaker with silent mediator of retinoic acid receptor and thyroid receptor (SMRT).^[@bib25],\ [@bib26]^ Although both of these co-repressors have been shown to regulate the activity of PPARγ in 3T3-L1 adipocytes,^[@bib27]^ their impact on LXR function in fat cells has not been investigated. Small heterodimer partner (SHP), is another repressor of LXR activity,^[@bib28]^ which can interact with LXR both in the presence and absence of ligand. Transgenic over-expression of SHP under the control of the aP2 promoter resulted in increased body weight, adiposity and propensity to develop diet-induced obesity.^[@bib29]^ However, the interaction between SHP and LXR has not been investigated in fat cells. Another possible co-repressor regulating LXR activity in human white adipocytes is the cell death-inducing DNA fragmentation factor-α-like effector A (CIDEA). CIDEA was recently shown to bind to LXR in *in vitro* and *ex vivo* systems and to repress LXR-regulated reporter constructs in 3T3-L1 cells.^[@bib30]^

Both LXR isoforms have been shown to co-localize and interact with receptor-interacting protein 140 (RIP140).^[@bib31],\ [@bib32]^ In non-adipose cells, RIP140 can function both as a co-activator and co-repressor of LXR. In hepatocytes for instance, RIP140 acts as a co-activator of LXR-induced lipogenesis, but as a co-repressor of genes regulating gluconeogenesis.^[@bib32]^ In brown adipocytes, RIP140 is recruited together with LXR to the enhancer region of *Ucp1*, encoding Uncoupling protein-1 (UCP1). This interferes with PPARγ binding to the same element and represses UCP1 expression.^[@bib33]^ PPARγ coactivator 1α (PGC-1α), a co-activator important for brown adipogenesis, has been shown to potentiate LXR activity in 3T3-L1 cells.^[@bib34]^ *In vitro* over expression of PGC-1α enhances ligand-dependent upregulation of LXRE-driven reporter constructs as well as endogenous expression of the *LXRα* gene. Recently, a novel co-regulator of LXR, G protein pathway suppressor 2 (GPS2), was identified.^[@bib35],\ [@bib36]^ GPS2 can also function both as a co-activator and co-repressor of LXR. However, there are presently no published data on the role of this co-factor in fat cells. Taken together, LXR can interact with a number of co-regulators that impact on its DNA-binding and transcriptional activity. As most studies in adipocytes have been performed in 3T3-L1 cells, the physiological role of these interactions in primary adipocytes and adipose tissue is not clear.

Post-transcriptional modifications
----------------------------------

The transcriptional activity of LXR and its interaction with co-factor complexes are affected by several post-transcriptional modifications. In hepatocytes, both LXR isoforms are acetylated in the unstimulated, ligand-free state. Upon ligand binding, a conformational change promotes LXR interaction with sirtuin 1 (SIRT1). This leads to de-acetylation at a conserved lysine residue (K432 in LXRα and K433 in LXRβ), which promotes the ubiquitination and degradation of the receptor. This implies that activation of LXR promotes increased degradation of the receptor, a common mechanism in NR signaling pathways. In the liver, induction of cholesterol transporters and SREBP-1c by LXR activation is dependent on SIRT1, demonstrating the importance of de-acetylation for LXR function.^[@bib37]^ In hepatocytes and macrophages, SUMOylation of LXR promotes the interaction with the co-regulators NR co-repressor and GPS2. This modification is required for trans-repression of inducible nitric oxide synthases and hepatic acute phase response genes.^[@bib36],\ [@bib38]^ LXRs can also be phosphorylated by protein kinase A (PKA), which impairs the activation of SREBP-1c transcription in hepatocytes.^[@bib39]^ Although it is not clear if post-translational modifications of LXR are present in adipocytes, all three isoforms of SUMO,^[@bib1],\ [@bib2],\ [@bib3]^ SIRT1 and protein kinase A are expressed in human fat cells and could therefore possibly regulate LXR activity in adipose tissue.

Role of LXR in adipogenesis
===========================

The role of LXR in regulating adipocyte differentiation is still a matter of debate. Different studies have reported stimulation, no effect or even suppression of adipogenesis by LXR ligands. In murine 3T3-L1 cells and human *in vitro*-differentiated Simpson-Golabi-Behmel syndrome (SGBS) pre-adipocyte cells, LXR expression is regulated by PPARγ and C/EBPα ^[@bib11],\ [@bib13],\ [@bib40],\ [@bib41]^---two transcription factors indispensible for adipogenesis. Functional PPARγ-binding elements are present in both the murine and human LXRα gene.^[@bib41]^ Several stimuli that interfere with adipogenesis, for example, ultraviolet light A, group X secretory phospholipase A2, several flavonoids, trans10, cis-12-conjugated linoleic acids (a group of polyunsaturated fatty acids), reduce the expression of LXRα, which in most cases is accompanied by a simultaneous downregulation of PPARγ.^[@bib24],\ [@bib42]^

Indirect evidence suggests that LXRα is regulated by PPARγ in human adipose tissue *in vivo* as well. Treatment of non-diabetic subjects with pioglitazone for 3 weeks resulted in a pronounced upregulation of LXRα mRNA expression.^[@bib43]^ However, the regulation by PPARγ may be more complex as both PPARγ and its target genes, including the fatty acid-binding protein aP2, are in turn LXRα target genes in adipocytes.^[@bib12],\ [@bib44]^

Previous studies reported that LXR activation during adipogenesis, potentiated fat accumulation in murine 3T3-L1 adipocytes and human fat cells.^[@bib11],\ [@bib12]^ Conversely, siRNA-mediated inhibition of LXRα suppressed adipocyte differentiation.^[@bib12]^ The adipogenic effect of LXR was proposed to be dependent on PPARγ as LXR activation had no effect on adipogenesis in PPARγ--/--mouse embryonic fibroblasts.^[@bib12]^ However, the pro-adipogenic effects of LXR in 3T3-L1 and 3T3-442A cells have not been confirmed by other groups.^[@bib45],\ [@bib46],\ [@bib47]^ It is worth pointing out that the studies showing positive effects also reported very low degree of differentiation in control cells and PPARγ agonists were not used in the differentiation medium. In contrast, the degree of adipocyte differentiation was high in the studies showing no or even negative effects of LXR.^[@bib45],\ [@bib46]^ It is quite plausible that these differences as well as the presence or absence of PPARγ agonists could explain the discrepancies between the studies.

Taken together*, in vitro* data suggest that the activation of LXR might enhance adipogenesis at least when PPARγ is only partly activated. However, when PPARγ is fully activated, LXR has no additional effect on adipocyte differentiation and could possibly even suppress it.^[@bib46]^ Therefore, LXR could act as a modulator of adipogenesis. The phenotype of LXR--/-- mice (discussed below) also implies that LXR is not indispensable for murine adipogenesis.^[@bib48],\ [@bib49]^

Whether LXR has a role in human adipogenesis, remains to be established. When human adipocytes are stimulated with GW3965 during late stages of *in vitro* differentiation, there are no effects on adipocyte morphology (Laurencikiene, unpublished observation) or on the expression of PPARγ and its target genes such as aP2.^[@bib44],\ [@bib50]^

LXR and lipid metabolism in adipocytes
======================================

Cholesterol transport
---------------------

LXRs are well-defined regulators of cholesterol transport and metabolism in the liver, intestine and macrophages where they upregulate the expression of the cholesterol transporters ABCA1, ABCG1, ABCG5/ABCG8, the rate-limiting enzyme in bile acid synthesis Cyp7A (in rodents, but not humans) and the high-density lipoprotein-associated apolipoprotein E (ApoE) (reviewed in Oosterveer *et al.*^[@bib5]^).

Adipose tissue contains the largest depot of cholesterol in the body,^[@bib15]^ which constitutes about 20% of the total intracellular cholesterol pool. This proportion can reach up to 50% in obesity. As cholesterol synthesis and catabolism are very low in fat cells, uptake and removal (that is, efflux via reverse cholesterol transport) are crucial for adipocyte turnover of cholesterol. Owing to the dynamic equilibrium between circulating and adipose cholesterol pools, adipose tissue can be considered as a 'buffering pool\' important for whole body cholesterol homeostasis (reviewed in Yu BL *et al.*^[@bib51]^).

In fat cells, LXR has been shown to upregulate the expression of several genes involved in cholesterol metabolism. In 3T3-442A adipocytes, endogenous or synthetic LXR agonists induce DNA binding to and activation of macrophage/adipocyte-specific enhancers in *ApoE*,^[@bib52]^ an integral component in reverse cholesterol transport. In murine adipose tissue, upregulation of ApoE by PPARγ ligands depends on the presence of LXR.^[@bib53]^ Other studies have confirmed the PPARγ-LXR-ABCG1/ABCA1/ApoE axis of regulation.^[@bib40],\ [@bib41],\ [@bib54],\ [@bib55]^ Moreover, niacin-induced cholesterol efflux in primary rat and 3T3-L1 adipocytes correlates with increased expression of LXRα.^[@bib56],\ [@bib57]^ In 3T3-L1 cells this is associated with increased mRNA expression of ABCA1.^[@bib57]^ SR-B1, a protein mediating cholesterol exchange between cells and high-density lipoprotein particles is also upregulated by LXR ligands in 3T3-L1 adipocytes.^[@bib58]^ The importance of LXR for the regulation of cholesterol transporters has been confirmed in murine knockout models (see below).

In human primary adipocytes, LXR regulates the expression of ABCG1 and ABCA1.^[@bib50]^ However, the role of these transporters in cholesterol efflux in human fat cells remains to be established.

Lipogenesis
-----------

LXR agonists are well-characterized inducers of hepatic lipogenesis (for review see Baranowski *et al.*^[@bib6]^) where both endogenous and synthetic LXR agonists induce lipid accumulation via stimulation of SREBP-1c and its response genes encoding key lipogenic enzymes (for example, fatty acid synthase (FAS), stearoyl-CoA desaturase-1 (SCD1), Acyl Co-Carboxylase 1 (ACC1) and aP2).^[@bib16],\ [@bib59]^ The lipogenic properties of LXR have also been investigated in various other cell types, including adipocytes.

Treatment of murine 3T3-L1 adipocytes with 22(R)-oxycholesterol or T0901317 during differentiation, increased lipid accumulation and the expression of SREBP-1c and FAS mRNA.^[@bib11],\ [@bib12]^ In addition, T0901317 upregulated the expression of both genes in murine adipose tissue *in vivo*.^[@bib12]^

In contrast, subsequent studies, including results from our own laboratory, provide strong evidence that the regulation of lipogenesis in adipocytes differs from that in the liver.^[@bib49],\ [@bib60],\ [@bib61]^ Sekiya *et al.*^[@bib60]^ showed that although LXR induced *SREBP-1c* gene expression in white adipose tissue (WAT) of mice and rats, this was not accompanied with increased expression of FAS. In line with this, SREBP1c was neither recruited to the FAS promoter nor did it induce the activity of a FAS promoter-driven reporter gene in adipocytes. The discrepancies between the findings discussed above might depend on experimental conditions, including different glucose or insulin concentrations that are known to influence lipogenesis. In any case, the role of SREBP-1c in fat cell lipogenesis can be questioned by data from SREBP-1c --/-- mice, as these animals develop diet-induced obesity similar to their wild-type littermates.^[@bib61]^ Furthermore, both basal and insulin-stimulated lipogenesis are increased in mature adipocytes isolated from LXRαβ--/-- mice as compared with wild-type mice.^[@bib49]^ Taken together, these data suggest that at least in rodent adipose tissue, LXR is not a primary regulator of lipogenesis.

Human adipocytes display very low rates of *de novo* lipogenesis. Stimulation of human primary adipocytes with LXR agonists for 7 days in culture has only marginal effects on the mRNA levels of SREBP-1c, FAS, ACC1 and SCD1.^[@bib62]^ If a PPARγ agonist is included into the adipogenic medium, T0901317 has no additional effect on the expression of lipogenic genes. Moreover, although short (24 h) stimulation of *in vitro*-differentiated human adipocytes with GW3965 slightly but significantly upregulates SREBP-1c mRNA, other lipogenic genes such as FAS, SCD1, ACC1 or aP2 are not affected (see Liu *et al.*^[@bib44]^, Stenson *et al.*^[@bib50]^ and unpublished observations). It is therefore not likely that LXR has a strong impact on *de novo* lipogenesis in differentiated human adipocytes.

Lipolysis
---------

Lipolysis, the enzymatic hydrolysis of triglycerides into free fatty acids and glycerol, is a pivotal process in adipocytes (reviewed in Lafontan and Langin^[@bib63]^). LXRs have been implicated in lipolytic regulation in several studies. Over-expression and activation of LXRα in murine 3T3-L1 adipocytes, upregulated basal but not hormone-stimulated release of free fatty acids.^[@bib46]^ Administration of T0901317 to mice, increased serum free fatty acid and glycerol concentrations, suggesting increased adipocyte lipolysis.^[@bib46]^ Similar treatments with GW3965 resulted in smaller fat cells, indicative of increased triglyceride utilization.^[@bib64]^

We could recently show that activation of LXR increases basal lipolysis in human fat cells. Chromatin immunoprecipation demonstrated that GW3965 induced binding of LXR/RXR heterodimers to the promoter regions of the genes encoding perilipin (PLIN1) and hormone-sensitive lipase (HSL), resulting in the downregulation of the corresponding mRNA levels.^[@bib50]^ PLIN1 and HSL are essential factors controlling lipolysis and the relative expression between these two proteins determines the lipolytic activity.^[@bib63]^ Our data suggested that the increase in basal lipolysis caused by LXR was primarily dependent on the decreased expression of PLIN1. In agreement with this hypothesis, higher PLIN1 (as well as HSL) expression levels have been observed in WAT from LXRαβ−/− mice when compared with wild-type littermates.^[@bib49]^

The role of LXR in regulating hormone-stimulated lipolysis is less clear. Although T0901317 treatments of 3T3-L1 adipocytes overexpressing LXRα did not change the maximal rate of free fatty acid or glycerol release upon stimulation with the β3--adrenoceptor agonist,^[@bib46]^ isolated murine LXRαβ--/-- adipocytes displayed three times higher maximal response to noradrenalin stimulation when compared with fat cells from wild-type littermates.^[@bib49]^ Treatments of human primary adipocytes with an LXR agonist influenced the expression of several genes regulating stimulated lipolysis.^[@bib50]^

Lipid oxidation
---------------

LXRs have also been implicated in lipid oxidation, another intracellular pathway controlling lipid utilization. In hepatocytes, activation of LXR increased peroxisomal β-oxidation,^[@bib65],\ [@bib66]^ whereas in myocytes LXR upregulated palmitate oxidation.^[@bib67]^ Activation of LXR in 3T3-L1 adipocytes increased the expression of the fatty acid elongation enzyme Elovl3,^[@bib45]^ an enzyme present in brown adipocytes that is induced by exposure to cold conditions and the expression of which correlates with fatty acid oxidation.^[@bib68]^ In agreement with this, studies in 3T3-L1 and human adipocytes have demonstrated that LXR activation shifts substrate oxidation toward utilization of lipids instead of carbohydrates.^[@bib69]^ LXR agonist GW3965 upregulated the expression of pyruvate dehydrogenase kinase 4 (PDK4), which resulted in the inhibition of the pyruvate dehydrogenase complex, a central enzyme controlling substrate utilization.

In contrast to findings in white fat cells, both LXR isoforms have been implicated in the negative regulation of oxidation and energy expenditure in brown adipocytes.^[@bib33],\ [@bib70]^ Thus, in murine brown adipocytes, LXR suppressed Elovl3 expression ^[@bib68]^ and, as mentioned previously, the LXRα/RIP140 complex suppresses the expression of UCP1 by preventing binding of PPARγ/PGC1α.^[@bib33]^ These findings are supported by data obtained in the LXR knockout animals (see below).

In summary, these data suggest a cell-specific role for LXR in adipocyte substrate oxidation and energy dissipation. While activation of LXR seems to upregulate lipid oxidation in white fat cells (via PDK4, Elov3), it suppresses energy dissipation in brown adipocytes (via UCP1, Elov3).

LXR and glucose uptake
======================

Glucose uptake in adipose tissue impacts on whole body glucose homeostasis. Two glucose transporters are responsible for glucose uptake in adipocytes. Glucose transproter-1 (Glut1) mediates basal glucose uptake, whereas Glut4 is mainly responsible for insulin-stimulated glucose transport (reviewed in Muretta *et al.*^[@bib71]^). Although several groups have studied the effects of LXR, there is no consensus on its role in adipose glucose transport. The first evidence that LXRs could regulate glucose uptake in fat cells was provided by Ross *et al.*^[@bib46]^ Over-expression of LXRα in 3T3-L1 adipocytes combined with T0901317 stimulation led to increased basal glucose uptake, upregulation of Glut1 expression and increased glycogen synthesis while insulin-stimulated glucose transport was not affected.

In contrast, Laffitte *et al.*^[@bib72]^ found that Glut4, but not Glut1 was upregulated by GW3965 in 3T3-L1 cells *in vitro* and in murine adipose tissue *in vivo*. Functional LXREs were found in both the murine and human Glut4 promoters (but were not reported in the Glut1 promoter). The LXRα/RXR dimer was shown to bind to these elements and to upregulate the activity of reporter constructs driven by Glut4 promoter.^[@bib72],\ [@bib73]^ Short (24 h) treatments with T0901317 induced Glut4 expression in wild type, LXRα--/-- and LXRβ--/-- adipose tissue, but not in fat from LXRαβ--/-- mice. Somewhat unexpectedly, the increase in Glut4 expression was abolished after longer (7 days) treatments.^[@bib73]^ Detailed analysis in different fat depots showed that Glut4 expression in epididymal fat was reduced in LXRα--/-- mice, suggesting that LXRα might be required for basal activity of the Glut4 promoter. In line with the increased expression of glucose transporters, it has been reported that LXR upregulates both basal and insulin-stimulated glucose uptake in 3T3-L1 adipocytes.^[@bib72],\ [@bib73]^ Taken together, the data discussed above suggest that LXR is a positive regulator of Glut4 and possibly Glut1 expression, and therefore of both insulin-stimulated and basal glucose uptake.

In contrast, several subsequent studies have not been able to confirm these findings. In cultured primary brown adipocytes from rat fetuses, LXR selectively upregulated Glut4, but not Glut1 protein expression and cell membrane localization.^[@bib74]^ Somewhat unexpectedly, basal but not insulin-stimulated glucose uptake was increased by T0901317 treatment in these cells, suggesting that mere expression of different glucose transporters on the cell membrane might not correlate with the rate and type of glucose transport.^[@bib74]^ The same conclusion was drawn in another study showing that the upregulation of Glut4 by LXR *in vivo* in rat epididymal fat was not associated with an increase in insulin-stimulated glucose uptake.^[@bib64]^ In two other *in vivo* studies, LXR activation lowered blood glucose, improved glucose tolerance and upregulated Glut4 expression only in adipose tissue from obese mice (ob/ob mice or diet-induced obese mice), but not in that from lean mice.^[@bib72],\ [@bib75]^ Accordingly, lean transgenic mice overexpressing LXRα in adipose tissue (under the control of the aP2 promoter) displayed no changes in systemic glucose metabolism.^[@bib76]^

Very few studies have addressed the role of LXR in regulating carbohydrate metabolism in human fat cells. In *in vitro* differentiated human SGBS adipocytes, T0901317 increased Glut4 mRNA levels by 50%, although the effect on glucose uptake was not investigated.^[@bib72]^

The discrepancies between the studies discussed above could be because of differences in agonists, *in vitro* cell models, treatment conditions as well as differences in age, weight and genotype of the mouse strains. In any case, it is apparent that the effect of LXR on the expression of glucose transporters and glucose uptake in adipocytes and adipose tissue is dependent on the metabolic and intracellular context. Therefore, the role of LXR in modulating glucose transport remains to be established.

LXR and inflammation in adipose tissue
======================================

Obesity is coupled to a chronic low-grade inflammatory state in WAT, characterized by the production of pro-inflammatory cytokines as well as infiltration and activation of macrophages, which affects systemic and local insulin sensitivity (reviewed in Ouchi *et al.*^[@bib77]^). Studies in rodents and different cell systems suggest that LXR is an important regulator of cytokine production in both adipocytes and macrophages.

LXR and inflammation in macrophages
-----------------------------------

LXR suppresses a pro-inflammatory phenotype in macrophages by repressing a set of inflammatory genes induced by either LPS, TNF-α or IL-1β.^[@bib78]^ This was suggested to be because of LXR\'s ability to interfere with NF-κB signaling in the nucleus.^[@bib79]^ Subsequent studies confirmed that SUMOylated, ligand-bound LXR, NR co-repressor and SMRT formed a complex that interfered with the DNA-binding ability of NF-κB, a central regulator of inflammatory pathways.^[@bib36],\ [@bib78],\ [@bib79],\ [@bib80]^ Moreover, in macrophages there is a cross talk between LXR and toll-like receptors (TLRs). LXR is known to directly regulate TLR4,^[@bib81]^ which could constitute another mechanism through which LXR attenuates inflammatory responses. Whether any of these effects are present in human macrophages in adipose tissue is not known.

LXR and inflammation in adipocytes
----------------------------------

The anti-inflammatory role of LXR in macrophages has prompted investigations into the cross talk between LXR and inflammatory cytokines in fat cells. Activation of LXR by a synthetic agonist fully restored insulin sensitivity in TNF-α-treated primary brown adipocytes.^[@bib74]^ This effect was mediated by the inhibition of protein tyrosine phosphatase 1B (PTP1B) production and restoration of the insulin-signaling cascade. Similar results were obtained in studies using the human liposarcoma cell line LiSa-2 that is able to differentiate into white adipocyte-like cells.^[@bib82]^ This cell line develops insulin resistance in the final stages of differentiation. In these cells, T0901317 restored insulin sensitivity and insulin-induced Akt phosphorylation, which was accompanied by reduced expression of IL-6 and MCP-1.^[@bib83]^ Furthermore, in LiSa-2 cells and human visceral adipocytes, T091317 and GW3965 counteracted insulin resistance and IL-6 secretion induced by TNF-α, which was mediated by attenuated JNK1/2 activity.^[@bib84]^

In addition to cytokines, LXR is a potential regulator of adiponectin and resistin. *In vivo* treatment of mice with T091317 resulted in a minor (20--50%) upregulation of resistin and adiponectin mRNA.^[@bib72]^ Slight upregulation of adiponectin mRNA by T0901317 was also observed in human Chub-S7 adipocytes, but not in the stroma-vascular fraction of human adipose tissue.^[@bib62]^ Clustering analysis of hypocaloric diet-regulated genes in human adipose tissue suggested that LXRα might regulate the expression of adiponectin receptors.^[@bib85]^ Yet, there is so far no strong experimental evidence indicating that LXR is an important regulator of adiponectin expression.

Taken together, these data suggest that although LXR may not have a major role in over-all adipokine secretion, it could attenuate the release of inflammatory cytokines in fat cells and possibly in adipose tissue macrophages.

Other intracellular pathways affected by LXR in adipocytes
==========================================================

Activation of LXRs in murine 3T3-L1 cells and in primary brown adipocytes reduces the expression and the activity of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1),^[@bib86]^ an effect which is abolished in LXRαβ--/-- mice. 11β-HSD1 converts inactive corticosteroids into biologically active glucocorticoids, such as cortisol, suggesting that LXR might interfere with peripheral glucocorticoid activation.

LXR could also have a role in vascularization of adipose tissue. This notion is based on the findings showing that LXR activation induces the expression of vascular endothelial growth factor in murine and human macrophages as well as in murine adipose tissue *in vivo*.^[@bib87]^ It has consequently been speculated that LXRs might counteract adipose tissue hypoxia in obesity.

Factors regulating LXR expression
=================================

Apart from pro-adipogenic factors, LXR expression and activity is regulated by a number of other mediators. The promoter of LXRα contains LXREs, enabling an autoregulatory loop in adipocytes and macrophages.^[@bib88]^ This may be important for the induction of LXR above a threshold necessary to regulate certain target genes.

Several steroid hormones affect LXR expression. Glucocorticoid treatment of *in vitro*-differentiated human subcutaneous and visceral adipocytes from severely obese subjects, induced the expression of 22 transcription factors, which included LXR.^[@bib89]^ However, whether this was mediated by direct or indirect regulation of the LXR genes is not clear. Estrogen (17β-estradiol) suppresses the activity of LXRα promoter--reporter constructs in 3T3-L1 cells as well as LXRα expression in murine adipocytes.^[@bib90]^

The expression of LXR in mouse WAT is downregulated by several pro-inflammatory factors, including LPS, TNFα and IL1β.^[@bib91]^ TNFα has been shown to downregulate the expression of LXRα and LXRβ in differentiated 3T3-L1 adipocytes and to suppress the activity of LXRE-driven reporter constructs.^[@bib91]^

In brown adipocytes and white fat cells expressing brown adipocyte-like features (inguinal fat), the expression of LXR and its target gene *SREBP-1c* is induced by cold exposure and β-adrenoceptor agonists, stimuli, which upregulate intracellular cAMP levels.^[@bib92]^ This finding might seem at odds with previously discussed data showing that LXR activation suppresses UCP1 expression in adipocytes.^[@bib33],\ [@bib93]^ However, it has been proposed in other cell types that LXR in its non-ligand-bound form might act as a cAMP-responsive transcription factor, regulating a different set of genes than those affected by oxysterol-activated LXR.^[@bib94]^ Whether this mechanism bears any relevance in white adipose tissue remains to be established.

Adipose phenotype of LXRα, LXRβ and LXRα/β knockout mice
========================================================

Isoform-specific (LXRα--/-- and LXRβ --/--) and double (LXRαβ--/--) knockout mice have been produced by two different laboratories. ^[@bib95],\ [@bib96],\ [@bib97]^ For LXRαβ--/--, both strains are glucose tolerant and insulin sensitive, and display 15--20% smaller adipose tissue depots than wild-type littermates.^[@bib11],\ [@bib61]^ The relative difference in adipose depot size compared with wild-type littermates increases with age. In addition, LXRαβ--/-- mice are resistant to diet-induced obesity and have significantly smaller adipocytes than wild-type littermates.^[@bib48],\ [@bib61],\ [@bib98]^ This could depend on attenuated adipogenesis, lipogenesis and/or increased fat utilization (lipolysis and/or lipid oxidation). In favor of the latter hypothesis is the finding that the LXRαβ--/-- mice generated by the Mangelsdorf laboratory show high expression of UCP1 in white adipose tissue and muscle, which results in high energy expenditure.^[@bib33],\ [@bib61]^ It has therefore been suggested that increased oxidation in adipose tissue and muscle constitutes at least a part of the mechanism protecting these mice from diet-induced obesity. In contrast, the LXRαβ--/-- strain developed in the Gustafsson laboratory shows increased expression of UCP1 in brown,^[@bib70]^ but not in white adipose tissue.^[@bib98]^

Conflicting results have been published regarding the endocrine function of adipocytes in LXRαβ--/-- mice. Thus, while one study reported a 50% reduction in leptin mRNA and no increase upon high fat diet,^[@bib48]^ another group using another mouse strain demonstrated that leptin concentrations were increased by 80% in the knockout mice.^[@bib98]^

The differences observed in these two strains could be explained by different genetic backgrounds including possible differences in the infiltration of brown or brown-like adipocytes in specific WAT depots.^[@bib49],\ [@bib98]^ In any case, despite tissue-specific differences in gene and protein expression, both strains of LXRαβ--/-- mice are likely to be protected against diet-induced obesity through increased metabolic rate.

The adipose tissue phenotype in LXR knockout animals has also contributed to the understanding of LXR function in specific tissues. Different sets of genes are affected by the absence of LXR in the liver or white and brown adipose tissue.^[@bib93]^ For example, LXR is required for basal expression of SREBP-1c in the liver but not in adipose tissue, suggesting that LXR may regulate lipogenesis via different mechanisms in adipocytes and hepatocytes.^[@bib49],\ [@bib99]^

Selective knockouts of LXR isoforms have confirmed that while some of LXR functions are redundant and can be mediated by both isoforms, others are unique and specific for LXRα or LXRβ. Gene expression profiling in gonadal WAT of wild type, LXRα--/-- and LXRβ--/-- mice showed that 443 genes were increased and 397 genes were decreased in LXRα--/--, while 155 genes were increased and 328 gene were decreased in LXRβ--/-- animals compared with wild-type littermates.^[@bib100]^ Gene ontology analysis revealed that genes coding for cytokines were preferentially regulated in LXRβ--/-- mice, whereas genes involved in carbohydrate metabolism seemed to be more LXRα specific. Genes belonging to lipid/cholesterol metabolism were equally affected in both mice strains.^[@bib100]^ Other studies have confirmed these findings. Thus, SREBP-1c, cholesterol transproters ABCG1 and ABCA1 were similarly regulated by LXR agonists in adipose tissue of both LXRα--/-- and LXRβ--/-- mice.^[@bib73],\ [@bib88]^ On the other hand, LXRβ--/-- mice were resistant to diet-induced obesity, had small fat cells and impaired fat storage in adipocytes.^[@bib48],\ [@bib98]^ Despite displaying a lean phenotype, LXRβ--/-- mice became insulin resistant on a high fat diet.^[@bib48],\ [@bib98]^ In contrast, LXRα--/-- mice accumulated visceral and subcutaneous fat on a high fat diet to a degree comparable with wild-type littermates. However, LXRα--/--animals remained insulin sensitive even on a high fat diet.^[@bib33],\ [@bib48],\ [@bib98]^

Adipose tissue-specific LXR knockout mice have not yet been generated. It is therefore difficult to identify the primary and secondary effects related to the absence of LXR in adipose tissue. Nevertheless, LXR knockout models have contributed to the understanding of how LXR isoforms as well as LXR in general may affect adipose function. [Figure 1](#fig1){ref-type="fig"} and [Table 1](#tbl1){ref-type="table"} summarize the reported roles of LXR (including α- and β-specific effects) in different adipose cell types.

Impact of LXR activation in metabolic diseases in animal models
===============================================================

A number of findings in animal models suggest that LXR activation could have a role in the treatment of common metabolic disorders, including hyperlipidemia, atherosclerosis and diabetes. In rodents, treatment with different LXR agonists reduces serum and hepatic cholesterol levels,^[@bib97]^ inhibits atherosclerosis^[@bib101],\ [@bib102],\ [@bib103]^ and improves glucose tolerance.^[@bib47],\ [@bib72],\ [@bib75]^ In most of these studies, the reported outcomes are primarily mediated by effects in non-adipose tissues. However, it should be noted that both T0901317 and GW3965 have been shown to increase serum and hepatic triglyceride levels, suggesting that these specific compounds may not be suitable for further clinical development. The development of isoform-specific or partial LXR ligands is an attractive possibility for new therapeutic agents. LXRβ-specific agonists are suggested to mediate anti-inflammatory effects and have beneficial influence on cholesterol metabolism without increasing hepatic lipogenesis. In addition, some partial LXR agonists lacking effects on hepatic lipogenesis have been developed.^[@bib103],\ [@bib104],\ [@bib105]^ The effects of these agonists in adipose tissue have not yet been investigated. The so far limited *in vitro* data from human macrophages and adipocytes support the notion that LXRβ stimulation may be preferred in a clinical setting because of its anti-inflammatory effects in macrophages and the fact that LXRα activation stimulates fat cell lipolysis--a well-established risk factor for insulin resistance.

Role of LXR in human obesity and insulin resistance
===================================================

A possible involvement of dysregulated LXR signaling in human obesity has been proposed in several independent studies. For example, the relative levels of LXRα in subcutaneous WAT were higher in a cohort of obese compared with age-matched lean women. Moreover, a SNP (rs2279238) and a haplotype of LXRα as well as two SNPs (LB44732G\>A and rs2695121) in LXRβ were associated with obesity in the same cohort.^[@bib9]^ A SNP (rs17373080) in the promoter region of LXRβ was associated with type 2 diabetes in a Norwegian cohort and with obesity/overweight in French and European cohorts.^[@bib8],\ [@bib10]^ However, *in vitro* studies have not been able to demonstrate any functional impact of the latter SNP on promoter activity.^[@bib8]^ In addition to genetic polymorphisms, expression of two LXR co-regulators (CIDEA and RIP-140) is downregulated in obese adipose tissue, which could result in altered LXR signaling.^[@bib106],\ [@bib107]^

Although data from murine models discussed above suggest that adipose tissue-specific treatments with LXR agonist could have several beneficial effects, including enhanced reverse cholesterol transport, increased glucose uptake, attenuated release of pro-inflammatory factors, increased lipid oxidation and reduced atherosclerosis, data on the systemic effects of LXR agonists in humans are lacking. To date, there is only one published study in humans, a phase 1 study that determined the effect of a non-isoform-specific LXR agonist.^[@bib108]^ The agent increased ABCG1 and ABCA1 mRNA in peripheral blood cells, but 55% of the subjects experienced neurological side effects, which could be because of the fact that LXR is expressed in the brain. This implies that an agonist for clinical use should not pass the blood--brain barrier. At present, there are no on-going clinical trials on LXR modulators, at least not reported in the US National Institutes of Health database (<http://ww.clinicaltrials.gov>). There could be many reasons for this. The integrated effect of LXR activation is dependent on the action in many organs, particularly in the liver. The positive actions of LXR on reverse cholesterol transport and hepatic gluconeogenesis could be counteracted by increased hepatic lipogenesis and adipocyte lipolysis, two processes promoting hyperlipidemia and insulin resistance. This demonstrates that LXR activation can have both positive and negative effects on metabolic parameters. Moreover, the fact that LXR shares its heterodimerizing partner (that is, RXR) with peroxisome proliferated activate receptors (PPARs) and sometimes competes for the same DNA-response elements, suggests that LXR activation could also affect PPAR signaling. Taken together, all these factors could lead to unexpected consequences when administering LXR activators *in vivo*. It is also important to note that the action of LXR appears to be species specific, making it difficult to translate data in animal models to a clinical situation. For example, LXR agonists have been reported to induce differential effects in primary rat versus human hepatocytes.^[@bib109]^ Similar studies comparing primary human and murine adipocytes are so far lacking.

In summary, given the scant data in human model systems, it is obvious that more studies are required to elucidate the effects of LXR in different tissues, the interactions between these effects and the outcome at the whole body level.
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![Summary of functions attributed to LXR in different cell types. The proposed role of LXR in different cellular processes are summarized for white and brown adipocytes as well as for macrophages. Where available, information on the main receptor-isoform (that is, α or β) mediating the effect is indicated. Positive (↑), negative (↓) or no (−) effects following LXR activation are indicated as reported in the literature. References are given in [Table 1](#tbl1){ref-type="table"}.](ijo201221f1){#fig1}

###### Summary of studies on LXR function in adipocytes

  *Process*                   *Experimental systems*                                                                                                                                                                                                                                                                            
  --------------------------- ----------------------------------------------------------------------------- ------------------------- ---------------------------------- ----------------------------------------------------------------------------------------------------------------- ------------------------------------ ---------------------------------------------------
  *Adipogenesis*              ↑ ^[@bib11],\ [@bib12]^ ↓ ^[@bib46]^ ↔ ^[@bib45],\ [@bib46],\ [@bib47]^       ↑ ^[@bib12],\ [@bib33]^   ND                                 ↔ ^[@bib45]\*,\ [@bib48],\ [@bib49],\ [@bib88]\*^ ↑ ^[@bib12]^                                                    ↑ ^[@bib62]^                         ↑ ^[@bib12]^ ↔ ^[@bib44]\*,[@bib50]\*,[@bib62]\*^
                                                                                                                                                                                                                                                                                                                                 
  *Lipid metabolism*                                                                                                                                                                                                                                                                                                            
   Cholesterol transport      ↑ ^[@bib45]\*,\ [@bib52]\*,\ [@bib53]\*,\ [@bib56],\ [@bib57]^ ^[@bib88]\*^   ↑ ^[@bib53]^              ND                                 ↑ ^[@bib45]\*,[@bib52]\*,[@bib57]\*,[@bib88]\*,[@bib64]\*^                                                        ↑ ^[@bib64]\*,[@bib88]\*^            ↑ ^[@bib50]\*^
   Lipogenesis                ↑ ^[@bib11],\ [@bib12]^ ↔ ^[@bib60]\*^                                        ↔ ^[@bib60]^              ↓ ^[@bib70]\*^                     ↓ ^[@bib49],[@bib98]\*^ ↔ ^[@bib60]\*,[@bib61]^ ↑ ^[@bib11]\*,[@bib12]\*^                                         ↑ ^[@bib62],[@bib83]\*^              ↑ ^[@bib62]\*^ ↔ ^[@bib44],[@bib50]\*^
   Lipolysis (basal)          ↑ ^[@bib46],\ [@bib50]^                                                       ND                        ↑ ^[@bib70]\*^                     ↑ ^[@bib46],\ [@bib49]^ ↔ ^[@bib48]\*,[@bib75]^                                                                   ↑ ^[@bib83]^                         ↑ ^[@bib50]^
   Lipolysis (stimulated)     ↔ ^[@bib46]^                                                                  ND                        ↔ ^[@bib33]\*^                     ↓ ^[@bib49]^                                                                                                      ND                                   ↓ ^[@bib50]\*^
   Oxidation                  ↑ ^[@bib45]\*,[@bib69]^                                                       ↓ ^[@bib33]^              ↓ ^[@bib33],[@bib68]\*,[@bib70]^   ↓ ^[@bib33],\ [@bib48],\ [@bib49]\*,\ [@bib61],\ [@bib70],\ [@bib98]^                                             ND                                   ↑ ^[@bib69]^
                                                                                                                                                                                                                                                                                                                                 
  *Glucose transport*                                                                                                                                                                                                                                                                                                           
   Basal                      ↑ ^[@bib46]^ ↔ ^[@bib72]^                                                     ND                        ↑ ^[@bib74]^                       ↑ ^[@bib46]^ ↔ ^[@bib72],\ [@bib73]^                                                                              ND                                   ND
   Insulin-stimulated         ↑ ^[@bib45]\*,[@bib72]\*,[@bib73]\*^ ↔ ^[@bib46],[@bib72]\*^                  ND                        ↔ ^[@bib74]^ ↑ ^[@bib70]\*^        ↑ ^[@bib88]\*,[@bib64],[@bib72]\*,[@bib73]\*,[@bib75]\*^ ↔ ^[@bib64],[@bib72],[@bib75]\*,[@bib76]^ ↓ ^[@bib49]^   ↑ ^[@bib73]\*,[@bib83]\*,[@bib87]^   ND
                                                                                                                                                                                                                                                                                                                                 
  *Endocrine role*                                                                                                                                                                                                                                                                                                              
   Adipokines, Leptin         ND                                                                            ND                        ND                                 ↑ ^[@bib48]^ ↓ ^[@bib98]^                                                                                         ND                                   ND
   Adiponectin                ND                                                                            ND                        ND                                 ↑ ^[@bib48],[@bib72]\*,[@bib98]^                                                                                  ↑ ^[@bib62]\*^ ↓ ^[@bib83]^          ↔ ^[@bib50]\*,\ [@bib62]\*^
   Pro-inflammatory factors   ND                                                                            ND                        ↓ ^[@bib74]^                       ND                                                                                                                ↓ ^[@bib83],\ [@bib84]^              ↓ ^[@bib84]^

Abbreviations: LXR, liver X receptor; ND, not determined.

The reported role of LXR as an activator (↑) or suppressor (↓) of intracellular processes in different adipose experimental systems. References demonstrating no effect of LXR are indicated by (↔). ^\*^Denotes that effects have only been demonstrated at the mRNA level.
